Joseph Stringer

Stock Analyst at Needham

(1.61)
# 1535
Out of 5,370 analysts
343
Total ratings
47.37%
Success rate
13.18%
Average return
23 Stocks
Name Action PT Current % Upside Ratings Updated
PHAT Phathom Pharmaceutic...
Maintains: Buy
28 28
10.6 164.15% 52 Jun 6, 2025
CDTX Cidara Therapeutics
Maintains: Strong Buy
35 36
22.5 60% 12 Jun 4, 2025
VIR Vir Biotechnology
Reiterates: Buy
14 14
5.24 167.18% 18 May 22, 2025
GILD Gilead Sciences
Reiterates: Hold
n/a
n/a n/a 6 May 21, 2025
INZY Inozyme Pharma
Downgrades: Hold
12 12
3.98 201.51% 20 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
16 11
2.43 352.67% 19 May 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
40 29
18.32 58.3% 20 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
66 72
62.34 15.5% 24 May 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 6 May 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
60 55
35.28 55.9% 21 Apr 30, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60 60
29.84 101.07% 17 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
22 22
11.7 88.03% 22 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
320 320
308.78 3.63% 21 Apr 9, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
90 90
34.23 162.93% 17 Apr 8, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 13 Mar 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
10 10
1.34 646.27% 17 Mar 4, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 8 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 16 Jun 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
37
22.12 67.27% 5 Jan 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 5 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
42 32
n/a n/a 1 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 1 Dec 13, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
32 18
10.74 67.6% 2 Aug 24, 2021